<?xml version="1.0" encoding="UTF-8"?>
<p>A computational study has suggested oseltamivir as a potential therapy for COVID-19, as it binds to the SARS-CoV-2 protease [
 <xref rid="B27-pharmaceuticals-13-00096" ref-type="bibr">27</xref>]. A clinical trial was registered to evaluate oseltamivir alone, in combination with ritonavir, or with ASC09F, in treatment of COVID-19. ASC09F is an investigational antiviral interferes with the virus life cycle and will be investigated in combination with oseltamivir and other antiviral agents in at least two trials (NCT04261270 and ChiCTR2000029603). 
</p>
